

**UNAUDITED FINANCIAL RESULTS**  
**FOR THE QUARTER ENDED 31ST DECEMBER, 2001**

*Rs in millions*

	Quarter Ended		Nine Months Ended		Year Ended 31.03.2001 (Audited)
	31.12.2001	31.12.2000	31.12.2001	31.12.2000	
1. Net Sales	3662.5	2756.4	10011.8	7870.9	10475.1
2. Other Income	152.5	81.6	333.1	257.4	386.1
3. Total Expenditure					
a) (Increase)/ decrease in Stock- in -trade	(320.3)	(182.9)	(366.9)	(360.5)	(375.8)
b) Consumption of Materials	1930.7	1478.4	4936.7	3968.8	5236.6
c) Staff Cost	158.6	116.9	462.0	354.5	499.0
d) Other Expenditure	1173.2	657.3	2969.8	2099.2	2961.1
4. Interest	7.8	2.9	15.0	8.2	8.3
5. Depreciation	48.5	40.0	143.5	122.5	156.3
6. Profit (+) / Loss (-) before Tax (1+2- 3-4-5)	816.5	725.4	2184.8	1935.6	2375.7
7. Provision for Taxation	*190.0	190.0	*510.0	495.0	585.0
8. Net Profit (+) / Loss (-)(6-7)	626.5	535.4	1674.8	1440.6	1790.7
9. Paid-up Equity Share Capital	599.7	599.7	599.7	599.7	599.7
10. Reserves excluding Revaluation Reserves ( as per balance-sheet of previous accounting year)	-	-	-	-	6540.5
11. Earning per Share **Not Annualised	**10.45	**8.93	**27.93	**24.02	29.86

**Notes :**

1.  
\* Provision for tax includes deferred taxation.
2.  
The Company is exclusively in the pharmaceutical business segment.
3.  
The Company is setting up facilities for manufacture of formulations at Verna, Goa at a capital expenditure of approximately Rs.1200 million. Commercial production has commenced in a phased manner.
4.  
The above results were taken on record at the meeting of the Board of Directors held on 19th January, 2002.

By order of the Board  
For **CIPLA LIMITED**

Mumbai  
19th January, 2002

**Dr. Y. K. Hamied**  
Chairman & Managing Director